亚洲AV片不卡无码久久蜜芽_国产精品免费久久久久影院_国产精品一区二区久久不卡_精品国产污污免费网站

語言選擇:簡體 / 繁體 / English

羅欣藥業 傳遞健康

山東羅欣藥業集團(tuan)股份有限公(gong)司招標公(gong)告(gao)

羅欣藥業 傳遞健康

羅欣藥業 傳遞健康

企業資訊

羅欣藥業宣布與JW Holdings簽署第三代三腔袋全腸外營養品獨家開發協議

發布時(shi)間:2020年10月26日 瀏覽次數:
分享:

羅(luo)(luo)欣藥(yao)(yao)(yao)業(ye)(ye)集(ji)團(tuan)股(gu)份(fen)有(you)限公(gong)司(股(gu)票代碼002793,簡稱(cheng)“羅(luo)(luo)欣藥(yao)(yao)(yao)業(ye)(ye)”)子公(gong)司山東羅(luo)(luo)欣藥(yao)(yao)(yao)業(ye)(ye)集(ji)團(tuan)股(gu)份(fen)有(you)限公(gong)司今天上(shang)午通過云簽約(yue)方式與韓國(guo)醫藥(yao)(yao)(yao)企業(ye)(ye)JW Holdings在(zai)線簽署合(he)作協議。針對JW Holdings旗下第三(san)代三(san)腔(qiang)袋全腸外(wai)營養品(pin)(pin)Winuf?,JW Holdings將授(shou)予(yu)羅(luo)(luo)欣藥(yao)(yao)(yao)業(ye)(ye)在(zai)中(zhong)國(guo)內地(di)、香港(gang)特別行政區、澳門特別行政區開發和(he)商業(ye)(ye)化(hua)該產(chan)(chan)品(pin)(pin)的(de)獨家權(quan)益。目前(qian)中(zhong)國(guo)國(guo)內尚無含魚油(you)三(san)腔(qiang)袋全腸外(wai)營養品(pin)(pin)上(shang)市。據悉,JW Holdings為歐洲GMP認證的(de)首(shou)個亞洲該類產(chan)(chan)品(pin)(pin)生產(chan)(chan)廠家。

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. , subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. (Stock Code: 002793, hereinafter referred to as "Luoxin Pharmaceutical"), signed an exclusive license and distribution agreement with JW Holdings through an online ceremony this morning. The agreement grants Luoxin Pharmaceutical the exclusive right to develop and commercialize Winuf? under JW Holdings in the Chinese mainland, Hong Kong and Macau. Winuf? is a three-chamber total parenteral nutrition (TPN) product and so far there are no commercialized TPN products containing refined fish oil on the Chinese market. Besides, JW Holdings is the first Asian TPN manufacturer certified by European GMP.

1.jpg

在線簽約儀式現場

Winuf?于2013年(nian)在韓國上(shang)(shang)市,并已經進(jin)入歐洲市場(chang)。該(gai)產品(pin)含(han)多種(zhong)脂類物質、葡萄糖(tang)及氨基(ji)酸,適用于無(wu)法通過腸內途徑攝取營(ying)養(yang)(yang)的患(huan)(huan)者(zhe)、大劑量放化療營(ying)養(yang)(yang)不(bu)良患(huan)(huan)者(zhe)、嚴重消化功能障礙患(huan)(huan)者(zhe)等人(ren)群。其(qi)(qi)精制魚油(you)含(han)量超過其(qi)(qi)他已上(shang)(shang)市三腔(qiang)(qiang)袋全腸外營(ying)養(yang)(yang)品(pin)規,可促進(jin)肝功能改善、促進(jin)人(ren)體(ti)脂代謝、有效抗(kang)炎(yan)并促進(jin)患(huan)(huan)者(zhe)免疫(yi)力(li)提升與(yu)恢復。該(gai)產品(pin)去年(nian)在韓國國內銷售額突破557億(yi)韓元;據IQVIA數據顯示,全球(qiu)三腔(qiang)(qiang)袋全腸外營(ying)養(yang)(yang)品(pin)市場(chang)份額增(zeng)長(chang)(chang)迅速,2017-2019年(nian)全球(qiu)市場(chang)年(nian)均(jun)增(zeng)長(chang)(chang)率達到(dao)(dao)9.1%,中國市場(chang)年(nian)均(jun)增(zeng)長(chang)(chang)率達到(dao)(dao)25.5%。

Launched in South Korea in 2013, Winuf? has also entered the European market. It consists of 4 lipid components, as well as glucose and amino acids. It’s suitable for patients who are not capable of enteral nutrition feeding, for malnutrition patients under high-dose radiotherapy or chemotherapy, and for patients with severe digestive dysfunction, etc. Winuf? contains a higher content of refined fish oil than other existing products, and promotes the improvement and recovery of immunity in patients. The domestic sales of Winuf? in South Korea were recorded as KRW 55.7 billion last year. According to IQVIA, the three-chamber TPN market is growing rapidly, with the average growth rate over the three years (2017-2019) of 9.1% globally and 25.5% in China.

根(gen)據協議(yi)條(tiao)款(kuan),羅欣藥(yao)(yao)業(ye)將(jiang)承擔Winuf?在中國(guo)(guo)境內的臨床(chuang)研究(jiu)、注冊和商(shang)業(ye)化(hua)相關活動。JW Holdings將(jiang)獲得(de)預付款(kuan),負(fu)責產(chan)(chan)品制造、供應(ying),并按中國(guo)(guo)未來產(chan)(chan)品銷售(shou)額獲得(de)相關里程(cheng)碑付款(kuan)和特許(xu)使(shi)用(yong)(yong)權費用(yong)(yong)。JW Holdings首(shou)席執行官Sung Kwon Han表示:“我們(men)相信羅欣藥(yao)(yao)業(ye)的臨床(chuang)研究(jiu)和商(shang)業(ye)化(hua)平臺能(neng)夠幫助(zhu)我們(men)將(jiang)Winuf?順利引進中國(guo)(guo)市(shi)場。我們(men)也希(xi)望借此契(qi)機將(jiang)Winuf?推向全球(qiu)市(shi)場,并期待未來與羅欣藥(yao)(yao)業(ye)拓展更多合作(zuo)空(kong)間(jian)。”

According to the terms of the agreement, Luoxin Pharmaceutical will undertake the clinical research, registration and commercialization of Winuf? in China. JW Holdings will receive the upfront payment, be responsible for product manufacturing and supply of Winuf?, and obtain sales milestone and tiered-royalties from Luoxin Pharmaceutical based on future sales in China. “We believe that Luoxin Pharmaceutical's platform of clinical research and commercialization can help us successfully introduce Winuf? into the Chinese market. We also hope to take this opportunity to promote the global opportunities of our product, and look forward to expanding our cooperation with Luoxin Pharmaceutical in the future, "said Sung Kwon Han, CEO of JW Holdings.

“我(wo)(wo)們(men)很高興(xing)與(yu)JW Holdings達(da)成此項合作協(xie)議(yi),也期(qi)待(dai)相(xiang)關產品(pin)盡快進(jin)(jin)入中(zhong)國(guo)市場(chang)并造福相(xiang)關適應(ying)癥患者(zhe)。” 羅欣藥業董事長(chang)劉振騰表示,“公司近年來與(yu)多(duo)家韓國(guo)企業合作,攜(xie)手促(cu)進(jin)(jin)多(duo)種優秀的產品(pin)和(he)療法進(jin)(jin)入中(zhong)國(guo)。我(wo)(wo)們(men)將(jiang)繼續堅持自主與(yu)合作研發的雙軌模式,打造更多(duo)能夠經受市場(chang)考驗的潛(qian)力管線(xian),為客戶(hu)、病患和(he)社(she)會各界創造最大的所需價值(zhi)空間(jian)!”

"We are very pleased to reach agreement with JW Holdings. We hope Winuf? will enter the Chinese market and benefit patients with relevant indications as soon as possible," said Ryan Liu, CEOof Luoxin Pharmaceutical. "In recent years, Luoxin Pharmaceutical has formed strategic partnerships with many Korean enterprises to introduce excellent products and therapies into China. We will attach equal importance to independent and cooperative R&D, create pipeline that can withstand the market test, and bring more value to customers, patients and the society! "

關于JW Group

JW集團(tuan)自1945成(cheng)立(li)以(yi)(yi)來,一直以(yi)(yi)尊重生(sheng)命(ming)和創新精神為理念拓展制藥研(yan)發,引領韓國(guo)本土市場,并于1959年開(kai)啟韓國(guo)首(shou)個(ge)“5%葡萄糖”醫院解決方案(an)。

其(qi)旗艦子公(gong)司JW Pharmaceutical擁有包(bao)括抗癌藥物在內的(de)各種(zhong)創新(xin)藥研發(fa)渠道。JW Life Science則是一(yi)家專門從事醫用注射劑(ji)生(sheng)產(chan)的(de)子公(gong)司,每(mei)年生(sheng)產(chan)和供應(ying)800萬種(zhong)綜合營養素,該公(gong)司也擁有全球最大的(de)環保非PVC醫用注射劑(ji)工廠。

JW控股(gu)除管(guan)理子公司之外(wai),還直接負責集團(tuan)原(yuan)材料(liao)、藥品和(he)醫(yi)療(liao)器械的海外(wai)業務。JW Holdings在韓國(guo)交易所(suo)上市,股(gu)票代碼(ma)為“096760”。

About JW Group

JW Group has been leading the Korean market for therapeutic drugs based on respect for life and the founding philosophy of pioneering spirit since its foundation in 1945. In 1959, the nation's first medical hospital solution, "5% glucose," has started its local manufacture.

JW Pharmaceutical, its flagship subsidiary, has various innovative new drug R&D pipelines, including anti-cancer drugs, while JW Life Science, a subsidiary specializing in hospital injection production, produces and supplies 8 million comprehensive nutrients annually based on the world's largest plant dedicated to eco-friendly Non-PVC hospital injections.
 JW Holdings is also directly responsible for overseas business of raw materials, drugs and medical devices in the group, in addition to managing subsidiaries, generating profits. JW Holdings is listed on the Korean exchange as '096760'.

 關于(yu)羅(luo)欣藥業

羅(luo)欣藥(yao)業(ye)集(ji)團股份有限公司(以(yi)下簡稱“羅(luo)欣藥(yao)業(ye)”)是集(ji)藥(yao)品研發(fa)、生產、貿易及(ji)醫療健(jian)康服務(wu)為(wei)一體的大型醫藥(yao)企業(ye)集(ji)團。躋身發(fa)展(zhan)速度(du)領先(xian)的中國制藥(yao)企業(ye)方陣,羅(luo)欣藥(yao)業(ye)致力于為(wei)客戶(hu)提供高品質原料(liao)藥(yao)、多劑型藥(yao)物(片劑、膠囊劑、注射劑等)和醫療健(jian)康服務(wu)。

羅欣(xin)藥業(ye)連(lian)續多(duo)年位列中國(guo)制(zhi)藥工(gong)業(ye)百強企(qi)業(ye)榜單(dan),且多(duo)次被評為“制(zhi)藥企(qi)業(ye)研發實力20強”,已于2019年登(deng)陸中國(guo)A股市場,股票代碼002793。

About Luoxin Pharmaceutical

Luoxin Pharmaceutical Group Stock Co., Ltd. is a healthcare conglomerate corporation in China that is engaged in pharmaceutical research and development, manufacture, sales, and healthcare service. As one of the fastest growing pharmaceutical companies in China, it serves customers with high quality active pharmaceutical ingredients (APIs), finished products in various formulation forms (tablets, capsules, injectable, etc.), and healthcare service.

Now the company has been ranking top 100 of China's Pharmaceutical Industry in terms of overall competence nationwide, and identified as one of the “Top 20 Pharmaceutical Companies with Strong R&D Pipelines” for years. The company was listed on China's A-shares market in 2019 as ‘002793’.